AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00883350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RIDE e-health application
Description: The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
Study NCT02405390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy
Description: Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
Study NCT02405390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
Study NCT02405390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz C-Mac® laryngoscope
Study NCT02405390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz C-Mac® laryngoscope
Study NCT01709292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib (All Groups)
Description: 960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
Study NCT01709292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib (Post Surgery) - Group A + C
Description: Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.~Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B.
Study NCT01709292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Surgery - Group B
Description: Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
Study NCT02183142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobic, China, 7.5 mg
Study NCT02374333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19
Study NCT02183142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic, China, 7.5 mg
Study NCT02183142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobic, Germany, 7.5 mg
Study NCT02616263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot exercise
Study NCT02183142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic, Germany, 7.5 mg
Study NCT01864941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter venography with balloon venoplasty
Description: All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
Study NCT01864941 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Catheter venography with balloon venoplasty
Description: All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
Study NCT01864941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter venography with balloon venoplasty and balloon
Study NCT00821483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Frovatriptan
Description: 2.5mg, qd
Study NCT00821483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frovatriptan
Description: 2.5mg, qd
Study NCT01689103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment of alcohol use disorders
Study NCT01689103 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment of alcohol use disorders
Study NCT01689103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment for alcohol use disorders
Study NCT01689103 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral treatment
Description: Cognitive-behavioral treatment for alcohol use disorders
Study NCT00993681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TD Vaccine System
Description: heat labile enterotoxin of E. coli (LT)
Study NCT00993681 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TD Vaccine System
Description: placebo
Study NCT03844100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efficacy and safety of CNU® Capsule
Description: All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
Study NCT03316365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
Study NCT03316365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Auditory Stimulation (RAS)
Description: The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
Study NCT03344796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal attainment
Description: After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
Study NCT03629210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZURDEX
Description: OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
Study NCT03629210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZURDEX
Description: OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
Study NCT03629210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eylea
Description: EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
Study NCT01635335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Latino STYLE
Description: 7-hour family-based workshop with 3-hour follow-up booster 3 months later
Study NCT01635335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latino STYLE
Description: 7-hour family-based workshop with 3-hour follow-up booster 3 months later
Study NCT01826071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretch
Study NCT01826071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Elongation
Study NCT04443530 — intervention group
Intervention type: DRUG
Intervention: Ultimaster™ Tansei™ stents
Description: Patients receiving Ultimaster™ Tansei™ stents
Study NCT00659750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus Placebo
Study NCT00659750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02616263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder exercise
Study NCT03199469 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Resamirigene bilparvovec
Description: Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
Study NCT02579759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PXT3003 dose 1
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study NCT02130024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Administered as an intravitreal injection
Study NCT02130024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2.0 mg
Description: Administered as an intravitreal injection
Study NCT02717273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: peri-operative antibiotic regimen only
Study NCT02717273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended
Description: extended three-day course of antibiotics
Study NCT02717273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liver transplant
Description: orthotopic liver transplantation
Study NCT02717273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: liver transplant
Description: orthotopic liver transplantation
Study NCT02643030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hypercapnia
Description: Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
Study NCT02643030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normocapnia
Description: Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
Study NCT02579759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PXT3003 dose 2
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study NCT02988882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02988882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study NCT03578731 — intervention group
Intervention type: DEVICE
Intervention: app
Description: The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app
Study NCT02630316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily
Study NCT02630316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered four times daily
Study NCT01118234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
Study NCT04314778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social incentive-based gamification
Description: At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
Study NCT03249350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Contingency Management (CM)
Description: CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks.
Study NCT03249350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Contingency Management (CM+)
Description: The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
Study NCT02619253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02619253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Study NCT02677896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT02677896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02806609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold water immersion, with 10 degrees, for 10 minutes
Description: cold water immersion
Study NCT02806609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: immersion in water at room temperature
Description: immersion in water at room temperature
Study NCT02806609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: active recovery - running
Description: active recovery
Study NCT02806609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rest in the chair
Description: rest in the chair
Study NCT03793530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
Description: Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
Study NCT03793530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal lumbar interbody fusion with local bone graft
Description: Transforaminal lumbar interbody fusion with local bone graft
Study NCT02658019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
Study NCT03066895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick
Description: Experimental device.
Study NCT03066895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lancing Device
Description: HMC standard of care.
Study NCT02466386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
Study NCT02579759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study NCT00670514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nix Individual
Description: Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
Study NCT00670514 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fimpa dig fri
Description: One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires.
Study NCT00747201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs Framework for the Bipolar Care Model
Description: Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
Study NCT00747201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Care Model Package Only
Description: Health care providers will receive only the adapted manuals.